AU2012267489B2 - System and method of cytomic vascular health profiling - Google Patents

System and method of cytomic vascular health profiling Download PDF

Info

Publication number
AU2012267489B2
AU2012267489B2 AU2012267489A AU2012267489A AU2012267489B2 AU 2012267489 B2 AU2012267489 B2 AU 2012267489B2 AU 2012267489 A AU2012267489 A AU 2012267489A AU 2012267489 A AU2012267489 A AU 2012267489A AU 2012267489 B2 AU2012267489 B2 AU 2012267489B2
Authority
AU
Australia
Prior art keywords
subject
microparticles
mps
cytometric
progenitor cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2012267489A
Other languages
English (en)
Other versions
AU2012267489A1 (en
Inventor
Andrew D. Bantly
Emile R. Mohler
Jonni S. Moore
Wade Rogers
Lifeng Zhang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Pennsylvania
Original Assignee
University of Pennsylvania
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Pennsylvania filed Critical University of Pennsylvania
Publication of AU2012267489A1 publication Critical patent/AU2012267489A1/en
Application granted granted Critical
Publication of AU2012267489B2 publication Critical patent/AU2012267489B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
    • G01N15/10—Investigating individual particles
    • G01N15/14—Optical investigation techniques, e.g. flow cytometry
    • G01N15/1456—Optical investigation techniques, e.g. flow cytometry without spatial resolution of the texture or inner structure of the particle, e.g. processing of pulse signals
    • G01N15/1459—Optical investigation techniques, e.g. flow cytometry without spatial resolution of the texture or inner structure of the particle, e.g. processing of pulse signals the analysis being performed on a sample stream
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AU2012267489A 2011-06-10 2012-06-10 System and method of cytomic vascular health profiling Ceased AU2012267489B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161495955P 2011-06-10 2011-06-10
US61/495,955 2011-06-10
US201261650353P 2012-05-22 2012-05-22
US61/650,353 2012-05-22
PCT/US2012/041792 WO2012170974A1 (en) 2011-06-10 2012-06-10 System and method of cytomic vascular health profiling

Publications (2)

Publication Number Publication Date
AU2012267489A1 AU2012267489A1 (en) 2014-01-09
AU2012267489B2 true AU2012267489B2 (en) 2017-03-16

Family

ID=47296510

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2012267489A Ceased AU2012267489B2 (en) 2011-06-10 2012-06-10 System and method of cytomic vascular health profiling

Country Status (7)

Country Link
US (1) US20140357505A1 (cg-RX-API-DMAC10.html)
EP (1) EP2717681A4 (cg-RX-API-DMAC10.html)
JP (1) JP6059211B2 (cg-RX-API-DMAC10.html)
CN (1) CN104039134A (cg-RX-API-DMAC10.html)
AU (1) AU2012267489B2 (cg-RX-API-DMAC10.html)
CA (1) CA2838436A1 (cg-RX-API-DMAC10.html)
WO (1) WO2012170974A1 (cg-RX-API-DMAC10.html)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160356774A1 (en) * 2014-03-07 2016-12-08 University Of Washington - Center For Commercialization Non-Invasive Biomarker of Antibody-Mediated Allograft Rejection
JP2015123503A (ja) * 2014-08-21 2015-07-06 千住金属工業株式会社 真空はんだ処理装置及びその制御方法
JP2018505392A (ja) * 2014-12-10 2018-02-22 ネオゲノミクス ラボラトリーズ， インコーポレイテッド 自動化されたフローサイトメトリ分析方法及びシステム
FR3030039B1 (fr) * 2014-12-12 2018-03-16 Commissariat A L'energie Atomique Et Aux Energies Alternatives Caracterisation et reproduction d'un jugement d'expert pour une classification binaire
CA3012985A1 (en) 2015-01-27 2016-08-04 Kardiatonos, Inc. Biomarkers of vascular disease
HK1249521A1 (zh) * 2015-05-07 2018-11-02 肿瘤免疫股份有限公司 Cd24用於降低低密度脂蛋白胆固醇水平的用途
US20190094244A1 (en) * 2016-03-22 2019-03-28 Inserm (Institut National De La Sante Et De La Recherche Medicale) Free Functional Annexin Levels in Plasma as a Biomarker of Cardiovascular Risk
JPWO2020138351A1 (cg-RX-API-DMAC10.html) * 2018-12-28 2020-07-02
WO2021062298A1 (en) 2019-09-27 2021-04-01 Arterez, Inc. Biomarker panel targeted to diseases due to multifactorial ontology of glycocalyx disruption
CN116359488A (zh) * 2021-12-27 2023-06-30 北京积水潭医院 检测血液样本中不同类型微颗粒含量的方法
CN114674729B (zh) * 2022-03-02 2023-11-21 迈克医疗电子有限公司 脉冲识别方法、装置、存储介质、设备及血液细胞分析仪
JPWO2024117233A1 (cg-RX-API-DMAC10.html) * 2022-12-02 2024-06-06
CN120778688B (zh) * 2025-07-09 2026-04-03 广州市微米生物科技有限公司 一种流式检测试剂在肿瘤疾病的出血风险等级分类产品中的应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090233999A1 (en) * 1999-09-06 2009-09-17 Novogen Research Pty Ltd Compositions and therapeutic methods involving isoflavones and analogues thereof
US7708977B2 (en) * 2002-11-15 2010-05-04 The United States Of America As Represented By The Department Of Health And Human Services Method for diagnosis and treatment of vascular disease
US20050032140A1 (en) * 2003-06-27 2005-02-10 Oklahoma Medical Research Foundation Methods for predicting susceptibility to cardiovascular disease
US20050272098A1 (en) * 2004-04-23 2005-12-08 Tramontano Anthony F Quantitation of endothelial microparticles
US20060078553A1 (en) * 2004-10-07 2006-04-13 Paul Glidden Diverse multi-unit complexes including a tRNA synthetase fragment
US20100203058A1 (en) * 2009-02-11 2010-08-12 Indiana University Research And Technology Corporation Diagnostics and therapeutics based on circulating progenitor cells
CA2765516A1 (en) * 2009-07-01 2011-01-06 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods for predicting cardiovascular mortality risk

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Curtis, et al., 'Relationship of microparticles to progenitor cells as a measure of vascular health in a diabetic population', Cytometry Part B: Clinical Cytometry, 2010, Vol. 78, pages 329-337. *

Also Published As

Publication number Publication date
EP2717681A4 (en) 2015-01-07
WO2012170974A1 (en) 2012-12-13
EP2717681A1 (en) 2014-04-16
US20140357505A1 (en) 2014-12-04
JP2014517313A (ja) 2014-07-17
AU2012267489A1 (en) 2014-01-09
CA2838436A1 (en) 2012-12-13
CN104039134A (zh) 2014-09-10
JP6059211B2 (ja) 2017-01-11

Similar Documents

Publication Publication Date Title
US20140357505A1 (en) System And Method Of Cytomic Vascular Health Profiling
Nielsen et al. A flow cytometric method for characterization of circulating cell‐derived microparticles in plasma
Li et al. Elevated circulating VE-cadherin+ CD144+ endothelial microparticles in ischemic cerebrovascular disease
Urrechaga et al. Role of leucocytes cell population data in the early detection of sepsis
Li et al. Single urinary extracellular vesicle proteomics identifies complement receptor CD35 as a biomarker for sepsis-associated acute kidney injury
JP7605502B2 (ja) Ｄｍａｒｄに対する患者の応答を予測する方法
Thulin et al. Circulating cell-derived microparticles as biomarkers in cardiovascular disease
US20250334589A1 (en) Methods for the detection and quantification of circulating endothelial cells
Siwaponanan et al. Enumeration and phenotyping of circulating microvesicles by flow cytometry and nanoparticle tracking analysis: Plasma versus serum
Zhang et al. Clinical characteristics and biomarkers feature analysis using a proteomics platform in young patients with acute coronary syndrome
EP2534491B1 (en) Compositons and methods for predicting cardiovascular events
WO2022101554A1 (en) Method for determining whether a subject is at risk of developing a chronic respiratory disease
De Simone et al. Circulating endothelial cell levels in psoriatic patients and their modification after an anti‐TNF‐alpha (Etanercept) treatment
Lou et al. Serum Pyroptosis-Related Cytokines as Biomarkers for Diagnostic Assessment and Risk Stratification of Ocular Graft-versus-Host Disease: A Case-Control Study
FI130377B (en) Procedure for determining whether a subject is at risk of developing an anxiety disorder
Yu et al. Analysis of the efficacy of a model for auxiliary diagnosis of aortic aneurysms based on clinical pathological features
Maréchal et al. Neutrophil dynamics in acute coronary syndrome
CA3208461A1 (en) Method for determining whether a subject is at risk of dying from breast cancer or prostate cancer
US20100120080A1 (en) Cancer diagnosis using ki-67
CN121476613A (zh) Ccl5作为免疫检查点抑制剂治疗肿瘤患者不良反应的预测性生物标志物及其应用
Li et al. Diagnostic Performance of Neutrophil Extracellular Traps–Related Biomarkers for Early Identification of Sepsis: A Prospective Cohort Study

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE NAME OF THE INVENTOR TO READ MOHLER, EMILE R.; MOORE, JONNI S.; ZHANG, LIFENG; ROGERS, WADE AND BANTLY, ANDREW D. - 29 -

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired